ACT-Accelerator – the next 7 days

WHO MS COVID-19 Briefing
24 September 2020
3 key issues upcoming in the next 7 days

1. **Core ACT-A documents**: release target 25 Sept
   - ACT-A Status Report & Plan
   - ACT-A Economic Investment Case

2. **ACT-A at UNGA**: 30 Sept, 8:30-10:00hr (EST)

3. **Rapid Diagnostics**: DG briefer (28 Sept); MS briefing (1 Oct)
The ACT-Accelerator Plan & Investment Case for release tomorrow, 25 September

Status Report & Plan provides an overview of ACT-Accelerator’s goal, approach, achievements to date & near-term priorities.

Investment Case provides an economic rationale for investing in ACT-A as a global, integrated, ‘end-to-end’ solution.

Developed collectively by Partners in consultation with the Facilitation Council
**ACT-A goal:** accelerated global access to tools that rapidly reduce risk of severe disease & end acute phase of pandemic.
ACT-A’s critical path uses accelerated & parallel workstreams to rapidly achieve its goal.

**R&D**
- 500+ actionable trials followed across products
- 100s of trials deep dived across geographies and sub-populations
- Regulatory approval and licensure of safe and efficacious tools

**Manufacturing**
- Procure / reserve scarce resources
- Manufacture products at risk
- Align on portfolio of candidates across products
- Reach global scale by expanding and allocating capacity

**Procurement**
- Perform rapid response procurement
- Set up advance commitments to shape market & ensure access for all countries
- Define allocation mechanisms based on framework
- Strike early-access deals

**Delivery**
- Define fair allocation framework to achieve equitable access
- Issue policies to inform usage
- Prepare for LIC / LMIC country delivery & infrastructure
- Launch and support deployment programs
- Sustain monitoring & learning

End the acute phase of the pandemic.
Some key landmarks from the start-up phase

- **Diagnostics**: new Ag RDT (+ EUL)
- **Vaccines**: COVAX Facility in business (159 countries & growing)
- **Allocation**: WHO Framework is the emerging standard
- **Therapeutics**: Dexamethasone now in rollout....

*Concrete outcomes of the ACT-Accelerator Collaboration*
### Immediate priorities for Sept – Dec 2020

<table>
<thead>
<tr>
<th>R&amp;D</th>
<th>Manufacturing</th>
<th>Procurement</th>
<th>Delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vaccines</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Add 1-5 candidates to portfolio based on imminent readouts</td>
<td>Negotiate new deals with manufacturers based on imminent Phase II/II results</td>
<td></td>
<td>Step up country preparedness efforts to deploy as soon as possible</td>
</tr>
<tr>
<td><strong>Therapeutics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evaluate new monoclonal antibodies and antivirals</td>
<td>Select molecules for 1st wave of manufacturing capacity reservations</td>
<td>Launch 3-5 further market interventions for repurposed medicines</td>
<td>Scale up Dexamethasone</td>
</tr>
<tr>
<td><strong>Diagnostics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accelerate evaluation of novel diagnostics</td>
<td>Roll out 10s of millions of antigen-detecting RDTs</td>
<td></td>
<td>Pre-empt deployment needs for antigen-detecting RDTs</td>
</tr>
</tbody>
</table>

**Cross-cutting priorities detailed in Plan**
Financing Requirements & Economic Rationale: the $US35 Bn is paid back in 36 hours, once int’l mobility & trade is restored

<table>
<thead>
<tr>
<th>Category</th>
<th>Total Ask</th>
<th>Proportion funded</th>
<th>Immediate gap(^1)</th>
<th>Funding gap(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutics</td>
<td>$7B</td>
<td>$0.3B</td>
<td>$4B</td>
<td>$7B</td>
</tr>
<tr>
<td>Vaccines</td>
<td>$16B</td>
<td>$2B</td>
<td>$7B</td>
<td>$14B</td>
</tr>
<tr>
<td>Diagnostics</td>
<td>$6B</td>
<td>$0.3B</td>
<td>$2B</td>
<td>$6B</td>
</tr>
<tr>
<td>Health Systems</td>
<td>$9B</td>
<td>$0.1B</td>
<td>$2B(^3)</td>
<td>$9B</td>
</tr>
<tr>
<td>Total Ask</td>
<td>$38B</td>
<td>$3B</td>
<td>$15B</td>
<td>$35B</td>
</tr>
</tbody>
</table>

1. Additional critical funding required by end of 2020 to meet ACT-Accelerator targets (excl. proportion already funded); 2. As of 7 September 2020; 3. Assuming 25% of total ask in 2020

Revenue losses of Travel and Tourism alone over 2020-2021

ACT-Accelerator Funding gap\(^1\)

$12T

Over 18 months

$0.7T

Over 1 month

$36B

Over 36 hours

$35B

Over 1 month

$3B

Over 36 hours

$2B

Immediate gap\(^1\)

$15B

Over 18 months

$2B

Immediate gap\(^1\)
Accelerating the end of the COVID-19 pandemic: taking new solutions to scale and making them equitably accessible, to save lives, protect health systems and restart the global economy

Concept: High-level side event on the ACT Accelerator at the 75th session of UNGA
30 September, 8:30-10:00am EST

Objectives
The overarching objectives of this event are to:

- Build stronger political consensus for a coordinated global response to COVID-19 and champion the importance and urgency of equitable access to new tools, especially effective vaccines.
- Catalyze a step change in support for the Access to COVID-19 Tools Accelerator (ACT-A), and its mechanisms like the COVAX Vaccines Facility, the most promising multilateral solutions for global equitable access to the tools needed to accelerate the end of the pandemic.

Context
The UN has from the outset of the pandemic been calling for global solidarity to combat COVID-19. The already overwhelming burden on health systems, and social and economic consequences, could deteriorate further with subsequent waves of the disease that could prove especially challenging for vulnerable countries and populations.
UNGA high-level event on ACT-Accelerator

- 30th September 2020, 08:30-10:00hr (EST)
- Convenor: UN Secretary-General  co-Hosts: UK, South Africa, WHO

Current Programme

Opening

High-level statements: human & economic toll; celebrate ACT-A collaboration & success, call for urgent political & financial support

Saving lives, protecting health systems & restarting global economy with new & existing tools

Statements: Heads of State/Gov’t, World Bank, UNAIDS, CSO
Economic, moral & political imperatives for a global, integrated end-to-end solution; roll out of new tests & treatments

Bringing a global solution to life: realizing full promise of ACT-A & its COVAX Facility

Statements and Panel: HoS, Industry rep, GAVI, CEPI, UNICEF
Showcase COVAX Facility and commitments

Closing & way forward

High level statements: new commitments, Call to Action

Registration opens 12.00EST, tomorrow (25 Sept) at https://access-for-all.world-television.com/register
The ACT-A Advocacy Campaign

Current focus

UNGA Event
30 Sept

Amplify the ACT-A ask to world leaders

World Bank/IMF Annual Meetings
12-18 Oct

Reinforce economic case & fiscal mechanisms

Paris Peace Forum
10-11 Nov

G20 Summit & related
Nov-Mar ’21

Series of commitments

Primary goal: translating political momentum into $US35 Bn in financing for ACT-A scale up & impact

Successful 1st ACT-A Council
10 Sept

Set stage for G20 Summit decisions

Outcome statement endorsed plan, economics & advocacy

G20 Fin/Hlth Min meeting
17 Sept

Amplify the ACT-A ask to world leaders
3 key issues upcoming in the next 7 days

1. **Core ACT-A documents**: release target 25 Sept
   - ACT-A Status Report & Plan
   - ACT-A Economic Investment Case

2. **ACT-A at UNGA**: 30 Sept, 8:30-10:00hr (EST)

3. **Rapid Diagnostics**: DG briefer (28 Sept); MS briefing (1 Oct)
Back up
ACT-A is a bold structure, driving unprecedented collaboration

Deep engagement of Principals, integrated workplans & budgets, working with the entire development system

Working with ...  
- Governments  
- Civil Society  
- Industry
The economic argument | unprecedented domestic stimulus has helped hedge the crisis but only in some sectors & countries

$US 10 trillion in stimulus unlocked by G20 countries to support businesses & economies

Size of stimulus package – in $B

Economic support is already showing mixed outlook

Financial indices – 100=1 Jan-20, as of 31 August 2020

EU unemployment rate – in % population

1 Source: OECD Data
Sectors that depend heavily on international trade & mobility will not recover with existing government stimulus